Jabba93 personal page - To The Moon

Jabba93

Jabba93

No personal profile

0Follow

0Followers

0Topic

0Badge

2023-10-27

I agree

Sorry, the original content has been removed

2023-07-14

Thoughts?

Nvidia Just Confirmed an Emerging AI Boom in Biotech

2023-07-11

Great ariticle, would you like to share it?

@JC888:Which Company Q2 Earning Will Save US Market?

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4141446122624682","uuid":"4141446122624682","gmtCreate":1678344591467,"gmtModify":1698354885064,"name":"Jabba93","pinyin":"jabba93","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/0c6ce3d9c54ff7e2e41c16f49736abb7","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":234834701549632,"gmtCreate":1698354351260,"gmtModify":1698355036607,"author":{"id":"4141446122624682","authorId":"4141446122624682","name":"Jabba93","avatar":"https://community-static.tradeup.com/news/0c6ce3d9c54ff7e2e41c16f49736abb7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4141446122624682","idStr":"4141446122624682"},"themes":[],"htmlText":"&nbsp;I agree&nbsp;","listText":"&nbsp;I agree&nbsp;","text":"I agree","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/234834701549632","repostId":"1198690081","repostType":2,"isVote":1,"tweetType":1,"viewCount":289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":197724070649904,"gmtCreate":1689306876436,"gmtModify":1689306892049,"author":{"id":"4141446122624682","authorId":"4141446122624682","name":"Jabba93","avatar":"https://community-static.tradeup.com/news/0c6ce3d9c54ff7e2e41c16f49736abb7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4141446122624682","idStr":"4141446122624682"},"themes":[],"htmlText":"Thoughts?","listText":"Thoughts?","text":"Thoughts?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/197724070649904","repostId":"2351473468","repostType":2,"repost":{"id":"2351473468","pubTimestamp":1689298032,"share":"https://ttm.financial/m/news/2351473468?lang=&edition=fundamental","pubTime":"2023-07-14 09:27","market":"us","language":"en","title":"Nvidia Just Confirmed an Emerging AI Boom in Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2351473468","media":"InvestorPlace","summary":"Trillion-dollar AI chipmaker Nvidia just announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.AI’s application in the field of biology holds the potential to unlock enormous economic value for one simple reason: data.The drug discovery and development process is prohibitively long and expensive, but AI can significantly shorten and cheapen this process. It can map out human genetic data, identify mutations, and run simulations of compounds to fight those mutations – all in an instant.Earlier this year, Japanese pharma giant Takeda Pharmaceutical bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using AI. And it isn’t alone.Editor’s note: “Nvidia Just Confirmed an Emerging AI Boom in Biotech” was previously published in June 2023. It has since been updated to include the most relevant information available.And Nvidia , the world’s preeminent AI company, may have just confirmed that sentiment yesterday.Nvidi","content":"<html><head></head><body><ul><li><p>Trillion-dollar AI chipmaker Nvidia just announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.</p></li><li><p>AI’s application in the field of biology holds the potential to unlock enormous economic value for one simple reason: data.</p></li><li><p>The drug discovery and development process is prohibitively long and expensive, but AI can significantly shorten and cheapen this process. It can map out human genetic data, identify mutations, and run simulations of compounds to fight those mutations – all in an instant.</p></li><li><p>Earlier this year, Japanese pharma giant Takeda Pharmaceutical bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using AI. And it isn’t alone.</p></li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/08fc2b90236392ee42dd7f0689243624\" tg-width=\"768\" tg-height=\"432\"/></p><p>Source: shutterstock.com/cono0430</p><p><em>Editor’s note: “Nvidia Just Confirmed an Emerging AI Boom in Biotech” was previously published in June 2023. It has since been updated to include the most relevant information available.</em></p><p>We’ve long said that artificial intelligence (AI) will have the most profound economic impact in the medical industry, where it can be used to accelerate and cheapen everything from drug discovery to patient treatment.</p><p>And <strong>Nvidia</strong> (<strong><u>NVDA</u></strong>), the world’s preeminent AI company, may have just confirmed that sentiment yesterday.</p><p>The trillion-dollar AI chipmaker announced a huge new partnership with biotech AI startup <strong>Recursion Pharmaceuticals</strong> (<strong><u>RXRX</u></strong>), which has developed a novel AI-driven platform for drug development and discovery.</p><p>Recursion will train its AI models on Nvidia’s cloud platform, which Nvidia will then license through its newly announced BioNeMo generative AI cloud service for drug discovery.</p><p>Nvidia will also pour $50 million into Recursion in exchange for a ~4% stake in the company.</p><p>This is a massive deal. Look no further than the 78% jump in RXRX stock yesterday after the news was announced.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/302f267f96ba1037d17616e58786246c\" tg-width=\"1033\" tg-height=\"651\"/></p><p><strong><em><u>But this is likely just the start of the big boom at the convergence of AI and medicine.</u></em></strong></p><p>Nvidia is a trillion-dollar juggernaut in the world of AI. It could’ve chosen any industry to commit its money and resources to. And of all industries, it chose biotechnology.</p><p>Why?</p><p><strong>Data.</strong></p><h2 id=\"id_2063034441\">In a World of Data, Today’s AI Is Just the Beginning</h2><p>Like computers, humans are nothing more than a bunch of data strung together. </p><p>At their core, computers are just a bunch of 1s and 0s coded in sequence, with each number corresponding to a certain action for the computer to perform. Human DNA is much the same. We’re just a bunch of As, Gs, Cs, and Ts strung together. Those are the four base types found in human DNA molecules, each determining a person’s characteristics, traits, and even actions. </p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8dabc8a2a3b96cd7936b0f4eb80e9f4c\" tg-width=\"1165\" tg-height=\"435\"/></p><p>Essentially, the connecting element here is data. </p><p>That means AI can have an <strong><em>especially profound impact on the human body. </em></strong></p><p>After all, at the end of the day, what is AI? It is just a machine learning algorithm processing tons of data to learn how to perform a certain task or variety of tasks. It’s all just algorithms and data, with data acting as the model’s “fuel.”</p><p>The quantity and quality of data an AI model has access to determines the quality of the model itself. </p><p>When it comes to the human body, there is no dearth of quality data. As mentioned above, we are nothing more than a bunch of quality genetic data strung together.</p><p><strong>Apply AI to all that data, and you will change the world. </strong></p><p>Seriously. </p><p>Consider the value proposition of Recursion’s core AI technology.</p><p>Currently, it takes about $900 million and 13.5 years to develop a new successful drug. With AI constantly running simulations, drug development could happen in months and for less than $100 million.</p><p>That may sound hard to believe, but it’s true. <em>Drugs are already being discovered by AI that quickly.</em></p><h2 id=\"id_2050184267\">AI Meets Biotech</h2><p>Earlier this year, Japanese pharma giant <strong>Takeda Pharmaceutical</strong> bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using artificial intelligence. </p><p>And it isn’t alone. </p><p>Other pharma giants like <strong>Bayer </strong>(<strong><u>BAYRY</u></strong>), <strong>Roche </strong>(<strong><u>RHHBY</u></strong>), <strong><a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> </strong>(<strong><u>SNY</u></strong>), and <strong>AstraZeneca </strong>(<strong><u>AZN</u></strong>) are actively using AI technology for drug discovery purposes. </p><p>The future of drug discovery starts now. </p><p><strong>This is big business. </strong></p><p>Research firm Deep Pharma Intelligence estimates that investments in the field of AI-powered drug discovery have tripled over the past four years to nearly $25 billion. Morgan Stanley believes that AI-powered drug discovery will lead to an additional 50 novel therapies being brought to market over the next decade, with annual sales in excess of $50 billion!</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5ee494fcf0431e3c1d2f995cb8e32fad\" tg-width=\"1174\" tg-height=\"594\"/></p><p>Source: Deep Pharma Intelligence</p><p>In other words, a $50 billion drug discovery revolution starts now. </p><p>Is your portfolio positioned for it?</p></body></html>","source":"investorplace_stock_picks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nvidia Just Confirmed an Emerging AI Boom in Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNvidia Just Confirmed an Emerging AI Boom in Biotech\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-07-14 09:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/hypergrowthinvesting/2023/07/ai-meets-biotech-transforming-the-drug-development-process/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Trillion-dollar AI chipmaker Nvidia just announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.AI’s application in the field of biology holds the potential to unlock ...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2023/07/ai-meets-biotech-transforming-the-drug-development-process/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","BK4534":"瑞士信贷持仓","BK4139":"生物科技","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","BAYRY":"Bayer A.G.","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","BK4543":"AI","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","BK4527":"明星科技股","BK4579":"人工智能","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","BK4588":"碎股","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","SNY":"赛诺菲安万特","BK4503":"景林资产持仓","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","RXRX":"Recursion Pharmaceuticals, Inc.","LU1316542783.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4581":"高盛持仓","BK4549":"软银资本持仓","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","BK4548":"巴美列捷福持仓","LU0642271901.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD-H","LU1435385759.SGD":"Natixis Loomis Sayles US Growth Equity RA SGD-H","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU0079474960.USD":"联博美国增长基金A","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","AZN":"阿斯利康","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0056508442.USD":"贝莱德世界科技基金A2","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","BK4539":"次新股","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","RHHBY":"罗氏控股","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","NVDA":"英伟达","LU0109392836.USD":"富兰克林科技股A"},"source_url":"https://investorplace.com/hypergrowthinvesting/2023/07/ai-meets-biotech-transforming-the-drug-development-process/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2351473468","content_text":"Trillion-dollar AI chipmaker Nvidia just announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.AI’s application in the field of biology holds the potential to unlock enormous economic value for one simple reason: data.The drug discovery and development process is prohibitively long and expensive, but AI can significantly shorten and cheapen this process. It can map out human genetic data, identify mutations, and run simulations of compounds to fight those mutations – all in an instant.Earlier this year, Japanese pharma giant Takeda Pharmaceutical bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using AI. And it isn’t alone.Source: shutterstock.com/cono0430Editor’s note: “Nvidia Just Confirmed an Emerging AI Boom in Biotech” was previously published in June 2023. It has since been updated to include the most relevant information available.We’ve long said that artificial intelligence (AI) will have the most profound economic impact in the medical industry, where it can be used to accelerate and cheapen everything from drug discovery to patient treatment.And Nvidia (NVDA), the world’s preeminent AI company, may have just confirmed that sentiment yesterday.The trillion-dollar AI chipmaker announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals (RXRX), which has developed a novel AI-driven platform for drug development and discovery.Recursion will train its AI models on Nvidia’s cloud platform, which Nvidia will then license through its newly announced BioNeMo generative AI cloud service for drug discovery.Nvidia will also pour $50 million into Recursion in exchange for a ~4% stake in the company.This is a massive deal. Look no further than the 78% jump in RXRX stock yesterday after the news was announced.But this is likely just the start of the big boom at the convergence of AI and medicine.Nvidia is a trillion-dollar juggernaut in the world of AI. It could’ve chosen any industry to commit its money and resources to. And of all industries, it chose biotechnology.Why?Data.In a World of Data, Today’s AI Is Just the BeginningLike computers, humans are nothing more than a bunch of data strung together. At their core, computers are just a bunch of 1s and 0s coded in sequence, with each number corresponding to a certain action for the computer to perform. Human DNA is much the same. We’re just a bunch of As, Gs, Cs, and Ts strung together. Those are the four base types found in human DNA molecules, each determining a person’s characteristics, traits, and even actions. Essentially, the connecting element here is data. That means AI can have an especially profound impact on the human body. After all, at the end of the day, what is AI? It is just a machine learning algorithm processing tons of data to learn how to perform a certain task or variety of tasks. It’s all just algorithms and data, with data acting as the model’s “fuel.”The quantity and quality of data an AI model has access to determines the quality of the model itself. When it comes to the human body, there is no dearth of quality data. As mentioned above, we are nothing more than a bunch of quality genetic data strung together.Apply AI to all that data, and you will change the world. Seriously. Consider the value proposition of Recursion’s core AI technology.Currently, it takes about $900 million and 13.5 years to develop a new successful drug. With AI constantly running simulations, drug development could happen in months and for less than $100 million.That may sound hard to believe, but it’s true. Drugs are already being discovered by AI that quickly.AI Meets BiotechEarlier this year, Japanese pharma giant Takeda Pharmaceutical bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using artificial intelligence. And it isn’t alone. Other pharma giants like Bayer (BAYRY), Roche (RHHBY), Sanofi (SNY), and AstraZeneca (AZN) are actively using AI technology for drug discovery purposes. The future of drug discovery starts now. This is big business. Research firm Deep Pharma Intelligence estimates that investments in the field of AI-powered drug discovery have tripled over the past four years to nearly $25 billion. Morgan Stanley believes that AI-powered drug discovery will lead to an additional 50 novel therapies being brought to market over the next decade, with annual sales in excess of $50 billion!Source: Deep Pharma IntelligenceIn other words, a $50 billion drug discovery revolution starts now. Is your portfolio positioned for it?","news_type":1},"isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":196571815354384,"gmtCreate":1689031952419,"gmtModify":1689040399591,"author":{"id":"4141446122624682","authorId":"4141446122624682","name":"Jabba93","avatar":"https://community-static.tradeup.com/news/0c6ce3d9c54ff7e2e41c16f49736abb7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4141446122624682","idStr":"4141446122624682"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/196571815354384","repostId":"196479556202736","repostType":1,"repost":{"id":196479556202736,"gmtCreate":1688989125760,"gmtModify":1688989228186,"author":{"id":"3570103090255456","authorId":"3570103090255456","name":"JC888","avatar":"https://community-static.tradeup.com/news/f3e3c0218599fca5c4e265ddbee1fb32","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570103090255456","idStr":"3570103090255456"},"themes":[],"title":"Which Company Q2 Earning Will Save US Market?","htmlText":"The US market rally pulled back in a holiday-shortened week. US Market Performance, Last Week: DJIA fell -2%, falling below its 21-day moving average (ma). S&amp;P 500 fell -1.2% to just below its 10-day ma. Nasdaq fell -0.9% and holding its 10-day ma. Advancing issues outnumbered decliners on the NYSE by a 2.49-to-1 ratio; on Nasdaq, a 2.00-to-1 ratio favored advancers Importance of the 10-day &amp; 20-day ma: 10 day ma: a powerful tool to know if prices are moving in an uptrend or a downtrend. 20 day ma: provides many more reversal signals than a 100-day moving average. The US Non-Farm Payroll (NFP) data was the main catalyst that affected the US market on Friday (see below). Nonfarm Payroll measures change in the number of people employed during the previous month, excluding the farming","listText":"The US market rally pulled back in a holiday-shortened week. US Market Performance, Last Week: DJIA fell -2%, falling below its 21-day moving average (ma). S&amp;P 500 fell -1.2% to just below its 10-day ma. Nasdaq fell -0.9% and holding its 10-day ma. Advancing issues outnumbered decliners on the NYSE by a 2.49-to-1 ratio; on Nasdaq, a 2.00-to-1 ratio favored advancers Importance of the 10-day &amp; 20-day ma: 10 day ma: a powerful tool to know if prices are moving in an uptrend or a downtrend. 20 day ma: provides many more reversal signals than a 100-day moving average. The US Non-Farm Payroll (NFP) data was the main catalyst that affected the US market on Friday (see below). Nonfarm Payroll measures change in the number of people employed during the previous month, excluding the farming","text":"The US market rally pulled back in a holiday-shortened week. US Market Performance, Last Week: DJIA fell -2%, falling below its 21-day moving average (ma). S&P 500 fell -1.2% to just below its 10-day ma. Nasdaq fell -0.9% and holding its 10-day ma. Advancing issues outnumbered decliners on the NYSE by a 2.49-to-1 ratio; on Nasdaq, a 2.00-to-1 ratio favored advancers Importance of the 10-day & 20-day ma: 10 day ma: a powerful tool to know if prices are moving in an uptrend or a downtrend. 20 day ma: provides many more reversal signals than a 100-day moving average. The US Non-Farm Payroll (NFP) data was the main catalyst that affected the US market on Friday (see below). Nonfarm Payroll measures change in the number of people employed during the previous month, excluding the farming","images":[{"img":"https://community-static.tradeup.com/news/b0e0665e8d5c4e115e8aa2272651f07d","width":"963","height":"232"},{"img":"https://community-static.tradeup.com/news/8b7a3f06e353ced25730fc7855ef2aaf","width":"1012","height":"421"},{"img":"https://community-static.tradeup.com/news/7ad6039220cc8fea066a8607cf2681e9","width":"1096","height":"23"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/196479556202736","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":9,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":179,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":234834701549632,"gmtCreate":1698354351260,"gmtModify":1698355036607,"author":{"id":"4141446122624682","authorId":"4141446122624682","name":"Jabba93","avatar":"https://community-static.tradeup.com/news/0c6ce3d9c54ff7e2e41c16f49736abb7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4141446122624682","authorIdStr":"4141446122624682"},"themes":[],"htmlText":"&nbsp;I agree&nbsp;","listText":"&nbsp;I agree&nbsp;","text":"I agree","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/234834701549632","repostId":"1198690081","repostType":2,"repost":{"id":"1198690081","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1698334038,"share":"https://ttm.financial/m/news/1198690081?lang=&edition=fundamental","pubTime":"2023-10-26 23:27","market":"us","language":"en","title":"U.S. GDP Grew at a 4.9% Annual Pace in the Third Quarter, Better Than Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=1198690081","media":"Tiger Newspress","summary":"US Gross domestic product was expected to increase at a 4.7% annualized pace in the third quarter, according to a Dow Jones consensus estimate.","content":"<html><head></head><body><p style=\"text-align: start;\">The US economy grew at its fastest pace in nearly two years during the past three months, once again defying predictions for a slowdown as many expected the Federal Reserve&#39;s monetary tightening to constrain the American consumer.</p><p style=\"text-align: start;\">The Bureau of Economic Analysis&#39;s advance estimate of third quarter US gross domestic product (GDP) showed the economy grew at an annualized pace of 4.9%<strong> </strong>during the period, faster than consensus forecasts.<strong> </strong>Economists surveyed by Bloomberg estimated the US economy grew at an annualized pace of 4.5% during the period.</p><p style=\"text-align: start;\">The reading came in higher than second quarter GDP, which was revised down to<strong> </strong>2.1%.</p><p>The GDP release highlights the resilience of the US consumer despite ongoing concerns of a slowdown. But many economists see this as the high water mark for economic growth before the credit tightening induced by the Federal Reserve&#39;s interest rate hikes and the recent rise in bond yields grabs hold of business development and consumer spending.</p><p style=\"text-align: start;\">&#34;Factoring tighter credit conditions, the restart of student loan payments, uncertainty regarding the lagged impact of monetary policy and a fragile global economic backdrop, real GDP growth is likely to drift below trend for several quarters,&#34; EY chief economist Greg Daco wrote in a research not prior to Thursday&#39;s release. &#34;We foresee real GDP growing a muted 1.4% in 2024 following expected growth of 2.4% in 2023.&#34;</p><p style=\"text-align: start;\">The key question for investors will be if the Fed has already tightened enough to bring the economy down from its hot third quarter, as Federal Reserve Chair Jerome Powell recently noted the central bank will need to see slower economic activity to ensure prices continue to cool.</p><p style=\"text-align: start;\">&#34;We certainly have a very resilient economy on our hands,” Powell said in a discussion at the Economic Club of New York. “Many forecasts called for the US economy to be in recession this year. Not only has that not happened; growth is now running for this year above its longer-run trend. So that&#39;s been a surprise.”</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. GDP Grew at a 4.9% Annual Pace in the Third Quarter, Better Than Expected</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. GDP Grew at a 4.9% Annual Pace in the Third Quarter, Better Than Expected\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2023-10-26 23:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p style=\"text-align: start;\">The US economy grew at its fastest pace in nearly two years during the past three months, once again defying predictions for a slowdown as many expected the Federal Reserve&#39;s monetary tightening to constrain the American consumer.</p><p style=\"text-align: start;\">The Bureau of Economic Analysis&#39;s advance estimate of third quarter US gross domestic product (GDP) showed the economy grew at an annualized pace of 4.9%<strong> </strong>during the period, faster than consensus forecasts.<strong> </strong>Economists surveyed by Bloomberg estimated the US economy grew at an annualized pace of 4.5% during the period.</p><p style=\"text-align: start;\">The reading came in higher than second quarter GDP, which was revised down to<strong> </strong>2.1%.</p><p>The GDP release highlights the resilience of the US consumer despite ongoing concerns of a slowdown. But many economists see this as the high water mark for economic growth before the credit tightening induced by the Federal Reserve&#39;s interest rate hikes and the recent rise in bond yields grabs hold of business development and consumer spending.</p><p style=\"text-align: start;\">&#34;Factoring tighter credit conditions, the restart of student loan payments, uncertainty regarding the lagged impact of monetary policy and a fragile global economic backdrop, real GDP growth is likely to drift below trend for several quarters,&#34; EY chief economist Greg Daco wrote in a research not prior to Thursday&#39;s release. &#34;We foresee real GDP growing a muted 1.4% in 2024 following expected growth of 2.4% in 2023.&#34;</p><p style=\"text-align: start;\">The key question for investors will be if the Fed has already tightened enough to bring the economy down from its hot third quarter, as Federal Reserve Chair Jerome Powell recently noted the central bank will need to see slower economic activity to ensure prices continue to cool.</p><p style=\"text-align: start;\">&#34;We certainly have a very resilient economy on our hands,” Powell said in a discussion at the Economic Club of New York. “Many forecasts called for the US economy to be in recession this year. Not only has that not happened; growth is now running for this year above its longer-run trend. So that&#39;s been a surprise.”</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198690081","content_text":"The US economy grew at its fastest pace in nearly two years during the past three months, once again defying predictions for a slowdown as many expected the Federal Reserve's monetary tightening to constrain the American consumer.The Bureau of Economic Analysis's advance estimate of third quarter US gross domestic product (GDP) showed the economy grew at an annualized pace of 4.9% during the period, faster than consensus forecasts. Economists surveyed by Bloomberg estimated the US economy grew at an annualized pace of 4.5% during the period.The reading came in higher than second quarter GDP, which was revised down to 2.1%.The GDP release highlights the resilience of the US consumer despite ongoing concerns of a slowdown. But many economists see this as the high water mark for economic growth before the credit tightening induced by the Federal Reserve's interest rate hikes and the recent rise in bond yields grabs hold of business development and consumer spending.\"Factoring tighter credit conditions, the restart of student loan payments, uncertainty regarding the lagged impact of monetary policy and a fragile global economic backdrop, real GDP growth is likely to drift below trend for several quarters,\" EY chief economist Greg Daco wrote in a research not prior to Thursday's release. \"We foresee real GDP growing a muted 1.4% in 2024 following expected growth of 2.4% in 2023.\"The key question for investors will be if the Fed has already tightened enough to bring the economy down from its hot third quarter, as Federal Reserve Chair Jerome Powell recently noted the central bank will need to see slower economic activity to ensure prices continue to cool.\"We certainly have a very resilient economy on our hands,” Powell said in a discussion at the Economic Club of New York. “Many forecasts called for the US economy to be in recession this year. Not only has that not happened; growth is now running for this year above its longer-run trend. So that's been a surprise.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":197724070649904,"gmtCreate":1689306876436,"gmtModify":1689306892049,"author":{"id":"4141446122624682","authorId":"4141446122624682","name":"Jabba93","avatar":"https://community-static.tradeup.com/news/0c6ce3d9c54ff7e2e41c16f49736abb7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4141446122624682","authorIdStr":"4141446122624682"},"themes":[],"htmlText":"Thoughts?","listText":"Thoughts?","text":"Thoughts?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/197724070649904","repostId":"2351473468","repostType":2,"isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":196571815354384,"gmtCreate":1689031952419,"gmtModify":1689040399591,"author":{"id":"4141446122624682","authorId":"4141446122624682","name":"Jabba93","avatar":"https://community-static.tradeup.com/news/0c6ce3d9c54ff7e2e41c16f49736abb7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4141446122624682","authorIdStr":"4141446122624682"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/196571815354384","repostId":"196479556202736","repostType":1,"repost":{"id":196479556202736,"gmtCreate":1688989125760,"gmtModify":1688989228186,"author":{"id":"3570103090255456","authorId":"3570103090255456","name":"JC888","avatar":"https://community-static.tradeup.com/news/f3e3c0218599fca5c4e265ddbee1fb32","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3570103090255456","authorIdStr":"3570103090255456"},"themes":[],"title":"Which Company Q2 Earning Will Save US Market?","htmlText":"The US market rally pulled back in a holiday-shortened week. US Market Performance, Last Week: DJIA fell -2%, falling below its 21-day moving average (ma). S&amp;P 500 fell -1.2% to just below its 10-day ma. Nasdaq fell -0.9% and holding its 10-day ma. Advancing issues outnumbered decliners on the NYSE by a 2.49-to-1 ratio; on Nasdaq, a 2.00-to-1 ratio favored advancers Importance of the 10-day &amp; 20-day ma: 10 day ma: a powerful tool to know if prices are moving in an uptrend or a downtrend. 20 day ma: provides many more reversal signals than a 100-day moving average. The US Non-Farm Payroll (NFP) data was the main catalyst that affected the US market on Friday (see below). Nonfarm Payroll measures change in the number of people employed during the previous month, excluding the farming","listText":"The US market rally pulled back in a holiday-shortened week. US Market Performance, Last Week: DJIA fell -2%, falling below its 21-day moving average (ma). S&amp;P 500 fell -1.2% to just below its 10-day ma. Nasdaq fell -0.9% and holding its 10-day ma. Advancing issues outnumbered decliners on the NYSE by a 2.49-to-1 ratio; on Nasdaq, a 2.00-to-1 ratio favored advancers Importance of the 10-day &amp; 20-day ma: 10 day ma: a powerful tool to know if prices are moving in an uptrend or a downtrend. 20 day ma: provides many more reversal signals than a 100-day moving average. The US Non-Farm Payroll (NFP) data was the main catalyst that affected the US market on Friday (see below). Nonfarm Payroll measures change in the number of people employed during the previous month, excluding the farming","text":"The US market rally pulled back in a holiday-shortened week. US Market Performance, Last Week: DJIA fell -2%, falling below its 21-day moving average (ma). S&P 500 fell -1.2% to just below its 10-day ma. Nasdaq fell -0.9% and holding its 10-day ma. Advancing issues outnumbered decliners on the NYSE by a 2.49-to-1 ratio; on Nasdaq, a 2.00-to-1 ratio favored advancers Importance of the 10-day & 20-day ma: 10 day ma: a powerful tool to know if prices are moving in an uptrend or a downtrend. 20 day ma: provides many more reversal signals than a 100-day moving average. The US Non-Farm Payroll (NFP) data was the main catalyst that affected the US market on Friday (see below). Nonfarm Payroll measures change in the number of people employed during the previous month, excluding the farming","images":[{"img":"https://community-static.tradeup.com/news/b0e0665e8d5c4e115e8aa2272651f07d","width":"963","height":"232"},{"img":"https://community-static.tradeup.com/news/8b7a3f06e353ced25730fc7855ef2aaf","width":"1012","height":"421"},{"img":"https://community-static.tradeup.com/news/7ad6039220cc8fea066a8607cf2681e9","width":"1096","height":"23"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/196479556202736","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":9,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":179,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}